MCID: EST001
MIFTS: 52

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to estrogen-receptor negative breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and Akt Signaling. The drugs Letrozole and Fulvestrant have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor negative breast cancer 30.3 AR ERBB2 ESR1 FOXA1 PGR
2 breast cancer 29.5 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
3 vestibular gland benign neoplasm 10.4 ESR1 PGR
4 bartholin's gland adenoma 10.4 ESR1 PGR
5 scirrhous adenocarcinoma 10.4 ERBB2 PGR
6 breast apocrine carcinoma 10.4 ERBB2 PGR
7 vulvar syringoma 10.4 ESR1 PGR
8 lung leiomyoma 10.4 ESR1 PGR
9 breast papillomatosis 10.4 CCND1 ERBB2
10 endometrium carcinoma in situ 10.4 PGR TP53
11 vulvar benign neoplasm 10.4 ESR1 PGR
12 trigonitis 10.4 ESR1 PGR
13 vulvar leiomyoma 10.4 ESR1 PGR
14 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
15 intracystic papillary adenoma 10.4 ERBB2 PGR
16 glassy cell carcinoma of the cervix 10.4 ERBB2 ESR1 PGR
17 breast metaplastic carcinoma 10.4 ERBB2 PGR
18 predominantly cortical thymoma 10.4 ESR1 PGR
19 breast medullary carcinoma 10.4 ERBB2 ESR1 PGR
20 breast scirrhous carcinoma 10.4 ERBB2 ESR1 PGR
21 bartholin's duct cyst 10.4 AR TP53
22 comedo carcinoma 10.4 ERBB2 ESR1
23 non-proliferative fibrocystic change of the breast 10.3 CCND1 ERBB2 TP53
24 adult hepatocellular carcinoma 10.3 PIK3CA TP53
25 inflammatory breast carcinoma 10.3 ERBB2 ESR1 PGR
26 female reproductive endometrioid cancer 10.3 ESR1 PGR TP53
27 sulfite oxidase deficiency due to molybdenum cofactor deficiency 10.3
28 cervical carcinosarcoma 10.3 ESR1 PGR TP53
29 lipid-rich carcinoma 10.3 ERBB2 ESR1 PGR
30 glycogen-rich clear cell breast carcinoma 10.3 ESR1 PGR TP53
31 mammary paget's disease 10.3 ERBB2 ESR1 PGR
32 oncocytic breast carcinoma 10.3 AR ESR1 PGR
33 progesterone-receptor negative breast cancer 10.3 ERBB2 PGR
34 tubular adenocarcinoma 10.3 ERBB2 ESR1 PGR
35 peritoneal benign neoplasm 10.3 AR ESR1 PGR
36 adenosarcoma 10.3 ESR1 PGR TP53
37 diffuse peritoneal leiomyomatosis 10.3 AR ESR1 PGR
38 bartholin's gland benign neoplasm 10.3 ESR1 PGR
39 microglandular adenosis 10.3 ERBB2 PGR TP53
40 uterine corpus serous adenocarcinoma 10.3 ERBB2 PIK3CA TP53
41 malignant spiradenoma 10.3 PIK3CA TP53
42 breast squamous cell carcinoma 10.3 ERBB2 PIK3CA TP53
43 mixed cell type cancer 10.3 ERBB2 PGR TP53
44 primary peritoneal carcinoma 10.3 ERBB2 PGR TP53
45 papillary adenocarcinoma 10.3 ERBB2 PGR TP53
46 esophageal disease 10.3 CCND1 ERBB2 TP53
47 dermatosis papulosa nigra 10.3 MTOR PIK3CA
48 postmenopausal atrophic vaginitis 10.3 AR ESR1
49 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
50 ovary adenocarcinoma 10.3 ERBB2 PIK3CA TP53

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

27 (show top 50) (show all 54)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.38 MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.38 HSPB8
3 Decreased viability GR00221-A-1 10.38 AKT1 ESR1 HSPB8 MTOR PIK3CA
4 Decreased viability GR00221-A-2 10.38 AKT1 ESR1 PIK3CA
5 Decreased viability GR00221-A-3 10.38 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.38 AKT1 ESR1 HSPB8 MTOR PIK3CA ERBB2
7 Decreased viability GR00301-A 10.38 HSPB8
8 Decreased viability GR00342-S-1 10.38 MTOR
9 Decreased viability GR00342-S-2 10.38 MTOR
10 Decreased viability GR00402-S-2 10.38 AKT1 ESR1 HSPB8 MTOR PIK3CA ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.24 MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.24 MTOR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.24 FOXA1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.24 FOXA1 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.24 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.24 FOXA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.24 NCOA3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.24 FOXA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.24 NCOA3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.24 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.24 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.24 AKT1 CCND1 FOXA1 PIK3CA MTOR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.24 CCND1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.24 PIK3CA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.24 AKT1 CCND1 FOXA1 NCOA3 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.24 FOXA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.24 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.24 CCND1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.24 FOXA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.24 CCND1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.24 CCND1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.24 FOXA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.24 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.24 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.24 AKT1 FOXA1 PIK3CA MTOR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.24 PIK3CA
37 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.24 AKT1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.24 FOXA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.24 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.24 MTOR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.24 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.24 NCOA3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.24 AKT1 MTOR
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.11 FOXA1
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.11 CCND1
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.11 MTOR
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.11 CCND1
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.11 CCND1
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.11 CCND1 FOXA1 PIK3CA
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.11 RAB31

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

47 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.43 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
3 behavior/neurological MP:0005386 10.41 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
4 endocrine/exocrine gland MP:0005379 10.4 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
5 cardiovascular system MP:0005385 10.37 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
6 growth/size/body region MP:0005378 10.36 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
7 immune system MP:0005387 10.36 AKT1 AR CCND1 CYP19A1 ESR1 FGFR2
8 mortality/aging MP:0010768 10.33 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
9 integument MP:0010771 10.31 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
10 adipose tissue MP:0005375 10.3 AKT1 AR CYP19A1 ESR1 FGFR2 MTOR
11 hematopoietic system MP:0005397 10.28 AKT1 AR CCND1 CYP19A1 ESR1 FGFR2
12 embryo MP:0005380 10.27 AKT1 AR ERBB2 ESR1 FGFR2 MTOR
13 digestive/alimentary MP:0005381 10.23 AR CCND1 CYP19A1 ERBB2 ESR1 FGFR2
14 muscle MP:0005369 10.21 AKT1 AR CYP19A1 ERBB2 ESR1 FGFR2
15 neoplasm MP:0002006 10.14 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
16 liver/biliary system MP:0005370 10.13 AKT1 AR CYP19A1 ESR1 FGFR2 NCOA3
17 normal MP:0002873 10.1 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
18 nervous system MP:0003631 10.07 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
19 reproductive system MP:0005389 9.93 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
20 renal/urinary system MP:0005367 9.86 AR CYP19A1 ESR1 FGFR2 MTOR NCOA3
21 respiratory system MP:0005388 9.56 AKT1 CCND1 ERBB2 ESR1 FGFR2 HSPB8
22 skeleton MP:0005390 9.4 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
2
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 104741 17756771
3
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120511-73-1 2187
4
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107868-30-4 60198
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
8
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177 70789204
9 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
11 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
12 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
13 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
22 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antifungal Agents Phase 4,Phase 3,Phase 2
27
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
28
Epirubicin Approved Phase 3 56420-45-2 41867
29
Fluorouracil Approved Phase 3 51-21-8 3385
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
31
Docetaxel Approved, Investigational Phase 3,Not Applicable 114977-28-5 148124
32
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
33
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Not Applicable 68-04-2
34
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
35
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3 154361-50-9 60953
36
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
37
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
38
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
39
Goserelin Approved Phase 3,Phase 2 65807-02-5 5311128 47725
40
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
41
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
42
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
43
Norepinephrine Approved Phase 3 51-41-2 439260
44
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
45
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
46
Testosterone Approved, Experimental, Investigational Phase 3 58-22-0, 481-30-1 6013 10204
47
Testosterone enanthate Approved Phase 3 315-37-7 9416
48
Methyltestosterone Approved Phase 3 58-18-4 6010
49
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
50
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
4 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
5 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
6 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
7 Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
8 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Recruiting NCT02947685 Phase 3 palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
9 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Enrolling by invitation NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
10 Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen;combination chemotherapy
11 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
12 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
13 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
14 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
15 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
16 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
17 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
18 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
19 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Completed NCT01598298 Phase 3 duloxetine hydrochloride
20 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
21 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
22 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
23 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
24 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
25 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
26 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
27 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
28 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
29 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
30 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
31 Metformin and Simvastatin in Addition to Fulvestrant Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
32 AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) Unknown status NCT01791985 Phase 1, Phase 2 AZD4547 / anastrozole or letrozole
33 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
34 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
35 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
36 Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
37 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer Not yet recruiting NCT03831711 Phase 1, Phase 2 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
38 Neoadjuvant Tamoxifen, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer Recruiting NCT03573648 Phase 2 Avelumab;Tamoxifen;Palbociclib
39 Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer Recruiting NCT02778685 Phase 2 Letrozole;Palbociclib
40 Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Completed NCT00093002 Phase 2 Fulvestrant
41 A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Active, not recruiting NCT01823835 Phase 2 GDC-0810;LHRH Agonist;Palbociclib
42 A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
43 Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
44 Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Recruiting NCT03566485 Phase 1, Phase 2 Atezolizumab;Cobimetinib;Idasanutlin
45 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Active, not recruiting NCT01142401 Phase 2 Bortezomib;Fulvestrant
46 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Recruiting NCT01984138 Phase 2 ESTRING;Replens
47 Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Terminated NCT01368263 Phase 2 goserelin acetate;letrozole;anastrozole;chemotherapy
48 Ruxolitinib in Estrogen Receptor Positive Breast Cancer Active, not recruiting NCT01594216 Phase 2 Ruxolitinib;Exemestane
49 TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Active, not recruiting NCT02988986 Phase 2 TAK-228;Tamoxifen
50 A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers Active, not recruiting NCT02238808 Phase 2 Estradiol

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

42
Breast, Bone, Lymph Node, Testes, Skin, Brain, Kidney

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 424)
# Title Authors Year
1
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer. ( 30824486 )
2019
2
Integrative molecular profiling identifies a novel cluster of ER-positive breast cancer in very young women. ( 30811755 )
2019
3
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. ( 30795773 )
2019
4
MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer. ( 30775882 )
2019
5
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. ( 29905023 )
2018
6
Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer. ( 29708591 )
2018
7
Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk. ( 29445914 )
2018
8
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. ( 29436393 )
2018
9
Expression signature of ten genes predicts the survival of patients with estrogen receptor positive-breast cancer that were treated with tamoxifen. ( 29928444 )
2018
10
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. ( 29562737 )
2018
11
miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. ( 29247596 )
2018
12
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( 29202611 )
2018
13
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 29450494 )
2018
14
Omega-3 Polyunsaturated Fatty Acids Time-Dependently Reduce Cell Viability and Oncogenic MicroRNA-21 Expression in Estrogen Receptor-Positive Breast Cancer Cells (MCF-7). ( 29342901 )
2018
15
Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer. ( 29782350 )
2018
16
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. ( 29128895 )
2018
17
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. ( 29127189 )
2018
18
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. ( 29733541 )
2018
19
Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer. ( 29765514 )
2018
20
A New Class of Agents for Estrogen-Receptor-Positive Breast Cancer. ( 29439601 )
2018
21
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. ( 29363090 )
2018
22
Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. ( 29373839 )
2018
23
Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. ( 29895278 )
2018
24
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. ( 29483206 )
2018
25
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. ( 29867779 )
2018
26
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. ( 29719270 )
2018
27
Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. ( 29626519 )
2018
28
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. ( 29352052 )
2018
29
18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer. ( 29485433 )
2018
30
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. ( 29676944 )
2018
31
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes. ( 30619463 )
2018
32
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. ( 30046001 )
2018
33
Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. ( 30053906 )
2018
34
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 30054636 )
2018
35
The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. ( 30061623 )
2018
36
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. ( 30089255 )
2018
37
21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. ( 30093354 )
2018
38
EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer. ( 30097312 )
2018
39
RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer. ( 30133331 )
2018
40
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. ( 30151737 )
2018
41
Radiation Therapy for Positive Surgical Margins in Women ≥70 Years with Stage I, Estrogen Receptor-positive Breast Cancer. ( 30194175 )
2018
42
Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. ( 30200915 )
2018
43
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. ( 30208932 )
2018
44
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy. ( 30214383 )
2018
45
Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer. ( 30250021 )
2018
46
Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. ( 30259117 )
2018
47
Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. ( 30275856 )
2018
48
Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. ( 30278072 )
2018
49
Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. ( 30343527 )
2018
50
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. ( 30368741 )
2018

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
2
Show member pathways
13.48 AKT1 AR CCND1 ERBB2 FGFR2 MTOR
3
Show member pathways
13.41 AKT1 CCND1 ERBB2 FGFR2 PIK3CA STAT5B
4
Show member pathways
13.03 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
5
Show member pathways
13.02 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
6
Show member pathways
12.93 AKT1 AR CCND1 PIK3CA STAT5B
7
Show member pathways
12.91 AKT1 ERBB2 FGFR2 MTOR PIK3CA
8
Show member pathways
12.83 AKT1 CCND1 MTOR PIK3CA STAT5B
9
Show member pathways
12.83 AKT1 AR CCND1 ERBB2 FGFR2 MTOR
10
Show member pathways
12.78 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
11
Show member pathways
12.77 AKT1 ERBB2 ESR1 MTOR PIK3CA TP53
12
Show member pathways
12.73 AKT1 CCND1 MTOR PIK3CA STAT5B
13
Show member pathways
12.66 AKT1 ERBB2 PIK3CA STAT5B TP53
14
Show member pathways
12.64 AKT1 CCND1 PIK3CA STAT5B TP53
15 12.59 CCND1 ERBB2 MTOR PIK3CA TP53
16
Show member pathways
12.59 AKT1 CCND1 ERBB2 MTOR PIK3CA STAT5B
17
Show member pathways
12.55 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
18
Show member pathways
12.55 AKT1 CCND1 ERBB2 ESR1 FGFR2 MTOR
19
Show member pathways
12.52 AKT1 CCND1 ERBB2 ESR1 FGFR2 MTOR
20
Show member pathways
12.51 AKT1 CCND1 MTOR PIK3CA TP53
21
Show member pathways
12.51 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
22
Show member pathways
12.48 AKT1 CCND1 MTOR PIK3CA STAT5B
23
Show member pathways
12.47 AKT1 FGFR2 MTOR PIK3CA
24
Show member pathways
12.47 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
25 12.43 AKT1 CCND1 PIK3CA STAT5B TP53
26
Show member pathways
12.42 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
27
Show member pathways
12.41 AKT1 AR PGR PIK3CA
28 12.36 CCND1 PIK3CA STAT5B TP53
29
Show member pathways
12.34 AKT1 CCND1 ERBB2 ESR1 NCOA3 PIK3CA
30
Show member pathways
12.31 AKT1 MTOR STAT5B TP53
31 12.3 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
32
Show member pathways
12.29 CCND1 ESR1 NCOA3 PGR
33
Show member pathways
12.24 AKT1 FGFR2 MTOR PIK3CA
34
Show member pathways
12.24 AKT1 MTOR PIK3CA TP53
35 12.24 AKT1 ERBB2 MTOR NCOA3 STAT5B
36 12.22 AKT1 CCND1 MTOR PIK3CA TP53
37
Show member pathways
12.21 AKT1 MTOR PIK3CA TP53
38
Show member pathways
12.21 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
39
Show member pathways
12.17 AKT1 AR CCND1 ERBB2 MTOR PIK3CA
40
Show member pathways
12.11 AKT1 ERBB2 PIK3CA TP53
41 12.1 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
42 12.09 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
43 12.05 AKT1 CCND1 MTOR TP53
44 12.03 AKT1 CCND1 ERBB2 PIK3CA TP53
45 11.99 AKT1 ERBB2 MTOR PIK3CA
46 11.98 AKT1 CCND1 PIK3CA STAT5B
47
Show member pathways
11.98 ERBB2 ESR1 PGR PIK3CA STAT5B
48 11.97 AKT1 MTOR PIK3CA STAT5B
49 11.96 AKT1 MTOR PIK3CA
50 11.96 AKT1 AR ESR1 MTOR

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 AKT1 AR CCND1 ERBB2 ESR1 HSPB8
2 protein-containing complex GO:0032991 9.63 AKT1 AR ESR1 MTOR NCOA3 TP53
3 nuclear chromatin GO:0000790 9.56 AR ESR1 NCOA3 TP53
4 nucleoplasm GO:0005654 9.4 AKT1 AR CCND1 ESR1 FGFR2 FOXA1
5 cytoplasm GO:0005737 10.18 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
6 nucleus GO:0005634 10.13 AKT1 AR CCND1 ERBB2 ESR1 FGFR2

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.98 AKT1 FOXA1 NUS1 TP53
2 cytokine-mediated signaling pathway GO:0019221 9.91 AKT1 CCND1 PIK3CA STAT5B TP53
3 positive regulation of gene expression GO:0010628 9.91 AKT1 AR ERBB2 MTOR NCOA3 TP53
4 protein phosphorylation GO:0006468 9.91 AKT1 CCND1 ERBB2 FGFR2 HSPB8 MTOR
5 positive regulation of protein phosphorylation GO:0001934 9.9 AKT1 CCND1 ERBB2 MTOR
6 transcription initiation from RNA polymerase II promoter GO:0006367 9.88 AR CCND1 ESR1 PGR
7 protein autophosphorylation GO:0046777 9.88 AKT1 ERBB2 FGFR2 MTOR
8 wound healing GO:0042060 9.86 ERBB2 FGFR2 MTOR
9 negative regulation of apoptotic process GO:0043066 9.85 AKT1 STAT5B TP53
10 multicellular organism growth GO:0035264 9.84 AR FGFR2 MTOR
11 cellular response to growth factor stimulus GO:0071363 9.79 AKT1 ERBB2 STAT5B
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 AKT1 FGFR2 MTOR
13 phosphatidylinositol phosphorylation GO:0046854 9.78 ERBB2 ESR1 FGFR2 PIK3CA
14 steroid hormone mediated signaling pathway GO:0043401 9.77 AR ESR1 PGR
15 response to estradiol GO:0032355 9.76 CCND1 ESR1 FOXA1 STAT5B
16 cellular response to epidermal growth factor stimulus GO:0071364 9.74 AKT1 ERBB2 STAT5B
17 phosphatidylinositol 3-kinase signaling GO:0014065 9.7 AKT1 ERBB2 PIK3CA
18 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.67 AR FOXA1
19 regulation of multicellular organism growth GO:0040014 9.67 FGFR2 PIK3CA STAT5B
20 Leydig cell differentiation GO:0033327 9.66 AR CCND1
21 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.66 ESR1 TP53
22 negative regulation of cell size GO:0045792 9.65 AKT1 MTOR
23 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
24 reproductive structure development GO:0048608 9.65 AR FGFR2
25 positive regulation of protein kinase B signaling GO:0051897 9.65 ERBB2 ESR1 FGFR2 MTOR PIK3CA
26 prostate gland epithelium morphogenesis GO:0060740 9.64 AR FOXA1
27 prostate gland growth GO:0060736 9.63 AR CYP19A1
28 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.63 ESR1 FGFR2
29 regulation of glycogen biosynthetic process GO:0005979 9.62 AKT1 MTOR
30 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.61 ESR1 FGFR2
31 mammary gland alveolus development GO:0060749 9.58 AR CCND1 ESR1
32 prostate epithelial cord elongation GO:0060523 9.56 ESR1 FGFR2
33 response to UV-A GO:0070141 9.55 AKT1 CCND1
34 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.54 AR PGR
35 negative regulation of macroautophagy GO:0016242 9.5 AKT1 MTOR PIK3CA
36 anoikis GO:0043276 9.33 AKT1 MTOR PIK3CA
37 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 AKT1 AR ESR1 FGFR2 FOXA1 NCOA3
38 positive regulation of transcription by RNA polymerase III GO:0045945 8.96 AR MTOR
39 regulation of transcription, DNA-templated GO:0006355 10.23 AR ESR1 FOXA1 NCOA3 PGR STAT5B
40 negative regulation of transcription by RNA polymerase II GO:0000122 10.12 AR CCND1 ESR1 FGFR2 FOXA1 TP53
41 positive regulation of cell proliferation GO:0008284 10.07 AKT1 AR CCND1 FGFR2 STAT5B

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.95 AKT1 ERBB2 ESR1 HSPB8 MTOR PGR
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 AR ESR1 PGR STAT5B TP53
3 kinase activity GO:0016301 9.91 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
4 protein kinase binding GO:0019901 9.89 AKT1 CCND1 ESR1 MTOR TP53
5 protein dimerization activity GO:0046983 9.78 AR ERBB2 NCOA3 STAT5B
6 protein kinase activity GO:0004672 9.73 AKT1 CCND1 ERBB2 FGFR2 HSPB8 MTOR
7 transcription factor binding GO:0008134 9.72 AR CCND1 ESR1 FOXA1 TP53
8 ATPase binding GO:0051117 9.71 AR ESR1 PGR
9 steroid hormone receptor activity GO:0003707 9.63 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
11 nitric-oxide synthase regulator activity GO:0030235 9.52 AKT1 ESR1
12 enzyme binding GO:0019899 9.43 AKT1 AR CCND1 ESR1 PGR TP53
13 steroid binding GO:0005496 9.33 AR ESR1 PGR
14 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 ERBB2 ESR1 FGFR2 PIK3CA
15 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.1 AR ESR1 FOXA1 NCOA3 PGR STAT5B
16 DNA-binding transcription factor activity GO:0003700 10.02 AR ESR1 FOXA1 PGR STAT5B TP53

Sources for Estrogen-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....